VivoSeq
Immunology

Behcet's Disease

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Behcet's Disease is an early-stage landscape with 0 programs across 2 companies. The most active players are Tanabe Pharma Corporation, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed7 · 58%
Unknown status5 · 42%

Clinical Trials

Trial Activity

12 trials

Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 3·NCT01532570·18 enrolled
Dusquetide for the Treatment of Behcet's Disease
Completed·SSoligenix·Phase 2·NCT06386744·8 enrolled
Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)
Completed·UUniversity Hospital Tuebingen·Phase 3·NCT00167583·37 enrolled
Low-dose IL-2 Treatment on Behcet's Disease
Completed·HHeJing·Phase 2·NCT04065672·60 enrolled
Phase III Study in Refractory Behcet's Disease
Completed·Novartis logoNovartis·Phase 3·NCT00995709·118 enrolled
Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease
Completed·TTehran University of Medical Sciences·Phase 2·NCT00700297·169 enrolled
Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
Completed·TTehran University of Medical Sciences·Phase 2·NCT00664599·20 enrolled
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease
Unknown status·TTehran University of Medical Sciences·N/A·NCT00931957·80 enrolled
Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis
Unknown status·—·N/A·NCT04022421·50 enrolled
Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease
Unknown status·—·Phase 4·NCT00720928·15 enrolled
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
Unknown status·SSilk Road Therapies, Inc.·Phase 2·NCT04186559·60 enrolled
Anti IL-18 (GSK1070806) in Behcet's Disease
Unknown status·—·Phase 2·NCT03522662·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)